Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 4

2(33.3%)

Phase 3

1(16.7%)

6Total

N/A(3)

Phase 4(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03327597Not ApplicableActive Not Recruiting

Iceland Screens, Treats or Prevents Multiple Myeloma

Role: collaborator

NCT02487524Not ApplicableCompleted

Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer

Role: collaborator

NCT02523287Phase 4Completed

Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses

Role: collaborator

NCT02555540Phase 4Completed

Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses

Role: collaborator

NCT02208206Completed

Analysis of Markers in the Blood Correlated With Neuropathic Pain

Role: collaborator

NCT00849563Not ApplicableCompleted

Effect of Type 2 Diabetes Genetic Risk Information on Health Behaviors and Outcomes

Role: collaborator

NCT00353067Phase 3Suspended

Veliflapon (DG-031)to Prevent Heart Attacks or Stroke in Patients With a History of Heart Attack or Unstable Angina

Role: lead

All 7 trials loaded